Near Infrared Spectroscopy in Sickle Cell Pediatric Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04031521 |
Recruitment Status :
Recruiting
First Posted : July 24, 2019
Last Update Posted : March 3, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Sickle Cell Disease | Diagnostic Test: Near infrared spectroscopy |
Study Type : | Observational |
Estimated Enrollment : | 40 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Near-infrared Spectroscopy in Sickle Cell Pediatric Patients During Pain Crisis and After Recovery |
Actual Study Start Date : | June 26, 2019 |
Estimated Primary Completion Date : | March 2, 2023 |
Estimated Study Completion Date : | June 30, 2023 |

Group/Cohort | Intervention/treatment |
---|---|
Sickle cell pain crisis |
Diagnostic Test: Near infrared spectroscopy
NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin. |
Sickle cell steady-state |
Diagnostic Test: Near infrared spectroscopy
NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin. |
- Tissue oxygenation [ Time Frame: 6 months ]
- Nitric oxide [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Years to 21 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria for Subjects with Sickle Cell Disease in Pain Crisis:
- Age 6 to 21 years old.
- Diagnosis of sickle cell anemia: a. Diagnosis of sickle cell disease (electrophoresis or HPLC documentation of hemoglobin SS, SC, S-beta-thalassemia or other hemoglobinopathies causing sickle cell disease is required).
- Acute onset pain crisis in a distribution typical for that subject, onset within the last 7 days and for which hospitalization and parenteral narcotic pain treatment are required.
- Ability to provide informed written consent.
Exclusion Criteria for Subjects with Sickle Cell Disease in Pain Crisis:
- Pregnancy.
- History of non-trivial injury, burns, surgery or skin ulcers on the arms.
- Fever or suspected sepsis at time of pain crisis
-
Administration of any of the following drugs within the last 14 days:
- Phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil)
- Endothelin-1 receptor blockers (bosentan, sitaxentan, ambrisentan, tezosentan)
- Nitric oxide donors (nitroglycerin, nitroprusside, nitrates)
- Ingestion of caffeine within the 12 hours before the start of the study appointment, or tobacco use within the 30 days before the study appointment.
-
Diagnosis with any of the following chronic diseases or conditions:
- History of high blood pressure
- History of high cholesterol
- History of diabetes
- History of chronic kidney disease (serum creatinine must not be greater than 2 mg/dL)
- History of coronary artery disease or peripheral vascular disease
- Received a blood transfusion within 7 days of the study procedure.
Inclusion Criteria for Subjects with Sickle Cell Disease in Steady State:
- Age 6-21 years
- Diagnosis of sickle cell disease (electrophoresis or HPLC documentation of hemoglobin SS, SC, S-beta-thalassemia or other hemoglobinopathies causing sickle cell disease is required).
- Ability to provide informed written consent.
Exclusion Criteria for Subjects with Sickle Cell Disease in Steady State:
- Pregnancy.
- History of non-trivial trauma, burns, surgery or skin ulcers on the arms.
- Fever or suspected sepsis at time of pain crisis
- Experience of an acute pain crisis requiring intravenous (IV) narcotics and hospital admission within the last 14 days.
- Ingestion of caffeine within the 12 hours before the start of the study appointment, or tobacco use within the 30 days before the study appointment.
-
Administration of any of the following drugs within the last 14 days:
- Phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil)
- Endothelin-1 receptor blockers (bosentan, sitaxentan, ambrisentan, tezosentan)
- Nitric oxide donors (nitroglycerin, nitroprusside, nitrates)
-
Diagnosis of any of the following chronic diseases or conditions:
- History of high blood pressure
- History of high cholesterol
- History of diabetes
- History of chronic kidney disease (serum creatinine must not be greater than 2 mg/dL)
- History of coronary artery disease or peripheral vascular disease
- Received a blood transfusion within 7 days of the study procedure.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04031521
Contact: Suvankar Majumdar, MD | 2024763800 | smajumdar@childrensnational.org |
United States, District of Columbia | |
Children's National Medical Center | Recruiting |
Washington, District of Columbia, United States, 20010 |
Responsible Party: | Suvankar Majumdar, Chief of Hematology, Children's National Research Institute |
ClinicalTrials.gov Identifier: | NCT04031521 |
Other Study ID Numbers: |
Pro00012424 |
First Posted: | July 24, 2019 Key Record Dates |
Last Update Posted: | March 3, 2023 |
Last Verified: | March 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia |
Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn |